Evaluation of risk factors for coinfection or cocolonization with vancomycin-resistant enterococcus and methicillin-resistant Staphylococcus aureus.
We retrospectively evaluated 410 patients with coinfection or cocolonization due to vancomycin-resistant (VR) enterococcus (VRE) and methicillin-resistant Staphylococcus aureus (MRSA). The prevalence rate was 19.8%. Risk factors included isolation of VR Enterococcus faecalis and use of linezolid or clindamycin. Inc18-like vanA plasmids were found in 7% of VR E. faecalis isolates and none of the VR E. faecium isolates.
Reyes
Katherine
K
Division of Infectious Diseases, Henry Ford Health System, Detroit, MI 48202, USA.
Malik
Rushdah
R
Moore
Carol
C
Donabedian
Susan
S
Perri
Mary
M
Johnson
Laura
L
Zervos
Marcus
M
D000081:Acetamides / Q000627:therapeutic use; D000368:Aged; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001426:Bacterial Proteins / Q000235:genetics; D019729:Carbon-Oxygen Ligases / Q000235:genetics; D002353:Carrier State / Q000453:epidemiology* / Q000382:microbiology*; D002981:Clindamycin / Q000627:therapeutic use; D015897:Comorbidity; D016983:Enterococcus / Q000187:drug effects / Q000302:isolation & purification*; D005260:Female; D016908:Gram-Positive Bacterial Infections / Q000453:epidemiology* / Q000382:microbiology*; D006801:Humans; D000069349:Linezolid; D008297:Male; D055624:Methicillin-Resistant Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification*; D008875:Middle Aged; D023303:Oxazolidinones / Q000627:therapeutic use; D010957:Plasmids; D015995:Prevalence; D012189:Retrospective Studies; D012307:Risk Factors; D020713:Vancomycin Resistance
D000081:Acetamides; D000900:Anti-Bacterial Agents; D001426:Bacterial Proteins; D023303:Oxazolidinones; C071437:VanA ligase, Bacteria; D002981:Clindamycin; D019729:Carbon-Oxygen Ligases; D000069349:Linezolid